Status and phase
Conditions
Treatments
About
A 2-stage (open-label run-in, followed by randomized, double-blind, placebo-controlled withdrawal) trial of setmelanotide in patients with obesity and specific gene defects variants in the melanocortin-4 receptor (MC4R) pathway.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
150 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Rhythm Clinical Trials; Physician Inquiry: Clinical Trials
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal